Solid Biosciences INC Schedule 13G passive stakes

FMR LLC, along with Abigail P. Johnson, has reported a beneficial ownership of 7.0% in Solid Biosciences Inc.'s common stock as of June 30, 2026.

BlackRock, Inc. has reported beneficial ownership of 6,419,730 shares, representing 6.5% of the outstanding common stock of Solid Biosciences Inc.

Invus Public Equities, L.P. and affiliated entities have reported beneficial ownership of 10,066,682 shares, representing 9.99% of Solid Biosciences Inc.'s outstanding common stock as of March 31, 2026.

BlackRock, Inc. has disclosed a beneficial ownership of 4.7% in Solid Biosciences Inc. as of March 31, 2026, holding 4,578,650 shares.

Adage Capital Management and its principals report a 1.8% beneficial ownership stake in Solid Biosciences Inc. as of December 31, 2025.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, reported a 5.14% beneficial ownership stake in Solid Biosciences Inc.

Commodore Capital LP and Commodore Capital Master LP have reported a 0.0% beneficial ownership in Solid Biosciences Inc., indicating a full divestment of their previous stake.

BlackRock, Inc. has filed a Schedule 13G, revealing a 6.1% beneficial ownership stake in Solid Biosciences Inc.'s common stock as of June 30, 2025.

Vestal Point Capital, LP and its Chief Investment Officer, Ryan Wilder, have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 2.3% in Solid Biosciences Inc.'s common stock.

Adage Capital Management, L.P. and its principals have filed a Schedule 13G, disclosing a passive beneficial ownership of 8.68% of Solid Biosciences Inc.'s common stock as of March 31, 2025.

Multiple Invus-affiliated entities and Raymond Debbane have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 9.6% in Solid Biosciences Inc.'s common stock as of March 31, 2025.

Commodore Capital LP and Commodore Capital Master LP have jointly reported a passive beneficial ownership of 7.6% in Solid Biosciences Inc., totaling 5,825,000 shares of common stock.

Camber Capital Management LP and Stephen DuBois have filed an amended Schedule 13G for Solid Biosciences Inc., indicating they no longer beneficially own any shares as of December 31, 2024.

A group of investment entities led by Raymond Debbane has filed an amended Schedule 13G, reporting a combined passive beneficial ownership of 9.4% in Solid Biosciences Inc. as of December 31, 2024.